Ian Tomlinson

Ian Tomlinson has a diverse work experience in the biopharmaceutical industry. Ian is currently the Chair of Maxion Therapeutics, a position they have held since April 2022. Prior to that, they served as the Founder Director and SAB Chair at Apollo Therapeutics from June 2021 to the present, and as the Chair from February 2016 to June 2021. Ian also served as the Chair of Start Codon from April 2019 to the present, and as the Chair of Stevenage Bioscience Catalyst from September 2015 to September 2020. Earlier in their career, Ian held various leadership roles at GSK, including Senior Vice President and Head of Worldwide Business Development from 2011 to February 2016, Senior Vice President and Head of Biopharmaceuticals R&D from November 2008 to February 2016, and VP of Biopharm CEDD from January 2007 to November 2008. Ian co-founded Domantis in 2001 and served as the Co-Founder, EVP, and CSO until January 2007 when it was acquired by GSK. Ian's career began as a Research Scientist at the MRC Laboratory of Molecular Biology, where they worked from September 1990 to June 2001.

Ian Tomlinson began their education at the University of Cambridge from 1987 to 1990, where they obtained their Bachelor of Arts degree in Zoology. Following this, they pursued their studies at The Open University from 1990 to 1995 and earned a Doctor of Philosophy (PhD) in Antibody Gene Sequencing and Mapping. Afterward, from 1993 to 1997, they served as a Junior Research Fellow at Trinity College Cambridge, specializing in Antibody Engineering.